# A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

> **NCT04458272** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 25 (estimated)

## Conditions studied

- WHO Grade II Glioma

## Interventions

- **DRUG:** DS-1001b

## Key facts

- **NCT ID:** NCT04458272
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-08
- **Primary completion:** 2023-03-10
- **Final completion:** 2026-08-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04458272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04458272, "A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04458272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*